Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment

NCT04358224 is registered in ClinicalTrials.gov with Jonathan A. Bernstein, MD as lead sponsor.

NCT NCT04358224
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04358224 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment
Lead sponsor
Jonathan A. Bernstein, MD
Phase
Phase 4
Overall status
Completed
Start date
September 1, 2020
Completion date
November 18, 2022
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis, eczema